Cargando…

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies

Detalles Bibliográficos
Autores principales:	Cavazzoni, Andrea, Digiacomo, Graziana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647643/ https://www.ncbi.nlm.nih.gov/pubmed/37947610 http://dx.doi.org/10.3390/cells12212532

Ejemplares similares

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
por: Digiacomo, Graziana, et al.
Publicado: (2021)

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
por: Cretella, Daniele, et al.
Publicado: (2019)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2023)

Strategies of solubility enhancement and perspectives in solubility measurements of pharmaceutical compounds
por: Bergström, Christel A.S., et al.
Publicado: (2020)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Rationale for launching a new journa
por: Nitrini, Ricardo
Publicado: (2007)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

A Novel Role for Extracellular Vesicles in Cytopathology and New Therapeutic Strategies
por: Tao, Shi-Cong, et al.
Publicado: (2019)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2022)

Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies
por: Wu, Lingxiang, et al.
Publicado: (2022)

Sarcomas: New Biomarkers and Therapeutic Strategies
por: Nakamura, Tomoki
Publicado: (2021)

New Therapeutic Strategies for Lung Cancer
por: Icard, Philippe, et al.
Publicado: (2021)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

The development of a new strategy in the management of bone and soft tissue tumors
por: Hamada, Yoshiki
Publicado: (2007)

Screening for congenital heart disease in India: Rationale, practical challenges, and pragmatic strategies
por: Kumar, Raman Krishna
Publicado: (2016)

EDITORIAL: Stroke—Pathophysiology and New Therapeutic Strategies
por: Kelley, Roger E.
Publicado: (2022)

The Rationale of Influenza
Publicado: (1891)

Chloroquine for COVID-19: rationale, facts, hopes
por: Cortegiani, Andrea, et al.
Publicado: (2020)

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

A new Journal section on Health Systems’ Research: purpose and rationale
por: Signorelli, Carlo, et al.
Publicado: (2017)

Rationale of the Action of Cocaine
Publicado: (1885)

Solubilization and Controlled Release Strategy of Poorly Water-Soluble Drugs
por: Peña, M. A.
Publicado: (2022)

New Strategies in Diagnosis and Treatments for Brain Tumors
por: Kantelhardt, Sven
Publicado: (2023)

Developing Cytokine Storm-Sensitive Therapeutic Strategy in COVID-19 Using 8P9R Chimeric Peptide and Soluble ACE2
por: Nazerian, Yasaman, et al.
Publicado: (2021)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

Plasma Cell Neoplasms: Genetics, Pathobiology, and New Therapeutic Strategies
por: Lee, Dong Soon, et al.
Publicado: (2014)

Stenting as a possible new therapeutic strategy to the obstructed TAPVC
por: Itoi, Toshiyuki
Publicado: (2013)

Cardiovascular prognosis: a new role for ceramides and other cardiometabolites
por: Wu, Jasmine M. F., et al.
Publicado: (2020)

The Tumor Boards – is this strategy worth for developing countries?
por: Pellizzon, Antonio Cassio de Assis
Publicado: (2018)

Developing Stem Cell-Based Therapeutic Strategies in Orthopaedic Surgery
por: Atesok, Kivanc, et al.
Publicado: (2018)

Neglected Tropical Diseases and Other Infectious Diseases Affecting the Heart. The NET-Heart Project: Rationale and Design
por: Burgos, Lucrecia M., et al.
Publicado: (2020)

Editorial: Special Issue “Addressing New Therapeutic Strategies Using Models”
por: Faustino-Rocha, Ana I., et al.
Publicado: (2023)

Development of targeted therapeutic strategies and refinement of sperm DNA fragmentation testing
por: Agarwal, Ashok, et al.
Publicado: (2017)

Extracellular Vesicles and Cell–Cell Communication: New Insights and New Therapeutic Strategies Not Only in Oncology
por: Gieseler, Frank, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1e6taktijg7chj2rv3uqihjihu